North America Neoantigens Market
North America consists of three countries, namely the US, Canada, Mexico. The US is the largest market for neoantigens, followed by Canada and Mexico. The growing numbers of clinical trials, growing advancements for immunotherapies to treat cancer, and growing support from the governments in the respective countries are driving the growth of market. Moreover, the significantly rising incidences of cancers in all the countries in the North American region are likely to serve growth opportunities for the market during the forecast period. The US is estimated to be the largest market for the neoantigens in the North American region. The growing numbers of clinical trials, increasing investments for research and development of neoantigens, rising collaborations between the companies are driving the growth of the market in the country. In addition, the significantly increased incidences of cancers are equally contributing to the growth of the market. The growing incidences of cancers have become a burden on the healthcare systems. Therefore, public and private players have initiated several programs to address the increasing incidences of cancers. To implement preventive and control measures, government and private agencies are supporting clinical trials for neoantigens. For instance, as per the publication of the FDA in November 2020, the FDA’s oncology staff receives support from the OCE Scientific Collaborative to participate in regulatory science research, such as internal research projects and collaborations with external experts. The OCE has identified FDA Broad Agency Announcement as a research funding method supporting nine areas of scientific interest, including cell/gene and personalized neo-antigen-based therapies for cancer. Therefore, OCE aims to facilitate regulatory works such as development, optimization and standardize the algorithm for neoantigens identification. Also, it aims to create approaches to evaluate the safety and efficacy of neoantigens. Further, it also aims to implement innovative clinical trials for neoantigen-based therapies. Moreover, various updated clinical trials are being published in the country. For instance, at American Association for Cancer Research Annual Meeting 2020, updates related to iNeST, developed by Roche’s Genentech and BioNTech for the combination therapy, were released. iNeST was combined with ICI and administered to patients living with solid metastatic tumors. Such developments for antigens are expected to leverage the growth of the market in the coming near future.
The impacts of COVID-19 pandemic are being felt across several markets in North America. Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing growing number of COVID-19 cases since its outbreak. For instance, according to WHO, from January 3, 2020 to May 5, 2021, there have been 32,123,136 confirmed cases of COVID-19 with 572,190 deaths. The cases are also increasing in Mexico and Canada. In Mexico, the cases have reached to 2,355,985 with 218,007 deaths. Similarly, in Canada, there are about 1,257,328 COVID-19 cases, with 24,450 deaths reported so far. In the US, many doctors, hospitals, and other healthcare facilities are delaying or canceling the cancer procedures, surgeries, and sometimes screenings or other treatments, if it is not considered urgent, emergency, or life-threatening condition. Due to weak immune system, cancer patients are requested to follow social distancing norms as they are more prone to get infected with virus that causes COVID-19. More research is being conducted on COVID-19 vaccines other than any other disease vaccine. For instance, a research study on “Cancer therapy tool informs COVID-19 vaccines” was published on April 2020 in Icahn School of Medicine at Mount Sinai, New York, NY, USA. In this study, a computational tool was designed to predict candidate neoantigens for cancer vaccines, which helps in the formation of T-cell vaccines against SARS-CoV-2. Pharmaceutical companies are halting ongoing studies and delaying the launch of new trials. Therefore, owing to these points, the pandemic is likely to affect cancer vaccine market.
Strategic insights for the North America Neoantigens provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 127,564.64 thousand |
| Market Size by 2028 | US$ 501,233.14 thousand |
| Global CAGR (2023 - 2028) | 31.5% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2028 |
| Segments Covered |
By Treatment
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The geographic scope of the North America Neoantigens refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The neoantigens market in North America is expected to grow from US$ 127,564.64 thousand in 2023 to US$ 501,233.14 thousand by 2028; it is estimated to grow at a CAGR of 31.5% from 2023 to 2028. Increasing prevalence of cancer; cancer has emerged as a leading cause death worldwide. According to the World Health Organization (WHO), cancer was the first leading cause of death in the people of age below 70 years in 183 countries and fourth leading cause of death in 123 countries worldwide in 2019. In addition, according to data published by the WHO in March 2021, ~10 million deaths occurred in 2020 due to different cancer type. The increasing prevalence of cancer has created burden on the healthcare systems across the world. According to International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~ 27.5 million by 2040, and the disease likely to be a cause of ~163 million deaths by that year. Factors such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions are likely to lead to even greater burden of cancer in the world in the coming years. Therefore, it is essential to control and prevent the increasing number of cancers worldwide This is bolstering the growth of the neoantigens market.
Based on treatment, the market is segmented into combination therapy, and mono therapy. In 2023, the combination therapy segment is estimated to have the largest share of the market. Based on
A few major primary and secondary sources referred to for preparing this report on the neoantigens market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Advaxis, Inc., Gradalis, Inc., Gritstone Oncology, Medigene AG, Moderna, Inc., and Ziopharm Oncology, Inc among others.
The North America Neoantigens Market is valued at US$ 127,564.64 thousand in 2023, it is projected to reach US$ 501,233.14 thousand by 2028.
As per our report North America Neoantigens Market, the market size is valued at US$ 127,564.64 thousand in 2023, projecting it to reach US$ 501,233.14 thousand by 2028. This translates to a CAGR of approximately 31.5% during the forecast period.
The North America Neoantigens Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Neoantigens Market report:
The North America Neoantigens Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Neoantigens Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Neoantigens Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Neoantigens Market
